Clinical Trial Update: Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bevacizumab and erlotinib in metastatic pancreatic cancer after gemcitabine failure; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-11-25